^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Dupert (fulzerasib) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Excerpt:
...have documentation of KRAS G12C mutation 3....
Trial ID:
Source:
Title:
A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
Excerpt:
...Have histologically or cytologically confirmed advanced KRAS G12C-mutated NSCLC....
Trial ID:
More C2 evidence
Source:
Title:
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
Excerpt:
...- Pathologically diagnosed, previously treated, advanced tumor with KRAS p.G12C mutation...
Trial ID:
Source:
Title:
Efficacy and Safety Evaluation of Fulzerasib in the Treatment of Advanced NSCLC with KRAS G12C Mutation: A Multicenter, Non-Interventional, Observational Study (IBI351-RWS-001)
Excerpt:
......
Trial ID:
Source:
Title:
Application of Fulzerasib in advanced NSCLC pts with KRAS G12C mutation, a indication application demonstration project
Excerpt:
......
Trial ID:
Source:
Title:
An open, multicentre, phase I/II study to evaluate the effectiveness and safety of IBI351 combined with platinum-containing chemotherapy and ⻉vazumab in subjects of KRAS G12C mutation or metastatic non-squamous non-small cell lung cancer subjects
Excerpt:
...1.Volunteer to participate in the research and sign the informed consent form; 2.≥18 years old and ≤75 years old when signing the informed consent form; 3.Expected survival time ≥3 months; 4.According to the 9th edition of the International Association for Lung Cancer Research and the Joint Commission for the Classification of Cancer in the United States, lung cancer TNM stage, locally advanced (phase III B/III C), metastatic or recurrent (phase IV) non-scale NSCLC subjects who cannot be surgically removed and cannot be subjected to radical synchronous radiotherapy confirmed by histology or cytology; 5.There is a clear test report proving that there is a mutation of KRAS G12C. ...
Trial ID:
Less C2 evidence
Source:
Title:
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
Published date:
05/26/2022
Excerpt:
IBI351(GFH925) was well-tolerated without unanticipated adverse events across all doses explored in pts with advanced solid tumors harboring the KRAS p.G12C mutation.
Trial ID: